Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study
William J. Sandborn, Silvio Danese, Jarosław Leszczyszyn, Jacek Romatowski, Engin Altıntaş, Elena Peeva, Mina Hassan‐Zahraee, Michael S. Vincent, Padmalatha S. Reddy, Christopher Banfield, M.P. Salganik, Anindita Banerjee, Jeremy D. Gale, Kenneth E. Hung
Topics & Concepts
MedicineUlcerative colitisPlaceboGastroenterologyInternal medicineClinical endpointConfidence intervalAdverse effectRandomized controlled trialPathologyDiseaseAlternative medicineInflammatory Bowel DiseaseRheumatoid Arthritis Research and TherapiesLiver Diseases and Immunity